Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + vincristine versus bevacizumab as second-line therapy for glioblastoma multiforme
PACTR202511863395261Phase 2Not yet recruiting
- Sponsor
- Esraa Mahmoud Mohamed Abdelmawla
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, vincristine and bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Esraa Mahmoud Mohamed Abdelmawla. Primary endpoint: response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
carboplatinvincristinebevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on PACTR202511863395261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511863395261.